E‹cient systemic siRNA delivery to cells in the target tissue is a current critical challenge in the drug deliveryˆeld. Several studies have demonstrated that nanoparticles such as polyethylene glycol (PEG)-coated siRNA-lipoplexes may enhance the systemic delivery of siRNA to tumor. However, the disordered tumor microenvironment still poses a potential impediment with respect to the e‹cient delivery of PEG-coated siRNA-lipoplexes. We recently showed that metronomic S-1 dosing (daily oral administration) enhanced the accumulation of PEG-coated liposome containing anticancer drug in solid tumor tissue and thereby increased therapeutic e‹cacy in tumor-bearing mouse model. To extend this work, we tried to investigate the eŠect of metronomic S-1 dosing on the intratumoral accumulation of PEG-coated siR-NA-lipoplex and, thereby, their therapeutic e‹cacy in solid tumor-bearing mouse model. Results showed that metronomic S-1 dosing improved systemic delivery of intravenously injected PEG-coated siRNA-lipoplexes into solid tumor tissue. In addition, the combined therapy of S-1 and PEG-coated siRNA-lipoplexes showed potent tumor growth suppressive eŠect. Our proposed strategy may pose a promising therapeutic one to conquer cancer progression with siRNA. 
From day 6 after LLCC inoculation, mice were orally treated with or without metronomic S-1 dosing (6.9 mg/kg) for 7 days and then received DiD-labeled PEG-coated siRNA-lipoplexes intravenously. At 24 h post-injection, in vivo optical images were taken at 1/15 s exposure time. Results shown are representative of three independent experiments. 10) 
